| Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor. | |
| | |
MedLine Citation:
|
PMID: 18521509 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The development of inhibitory antibodies to factor VIII is a serious complication of haemophilia. Two haemostatic agents with different bypassing mechanisms have been used in the treatment of patients with inhibitors: activated prothrombin complex concentrate (aPCC) and recombinant factor VIIa (rFVIIa). The objective was to compare cost and outcome of aPCC and rFVIIa in the treatment of joint bleeds. The analyses were based on the FENOC (FEIBA NovoSeven Comparative Study) crossover study where 48 patients used aPCC and rFVIIa to treat two joint bleeds. Incremental cost-effectiveness ratios were calculated for three outcome measures and the variation in cost was analyzed using two alternative regression methods. Results were subjected to sensitivity analyses. Key determinants of cost were prescribed dose, bodyweight and treatment in addition to protocol. The cost of aPCC was on average lower than rFVIIa. At all but one time point, patients rated slightly higher (but not statistically significantly) percentages of treatment efficacy and stopping of the bleed by aPCC. The reported reduction in pain from start of treatment up to 48 hours varied considerably among individuals. The different relative prices in the US, Turkey and Sweden mattered, but did not reverse the main results. In conclusion, the cost per episode was significantly lower for aPCC. The large individual-level variation in reduction of pain supports decisions that consider the individual patient's experience and that accept trade-offs between cost and reduction in pain rather than focusing on cost only. |
| | |
Authors:
|
Katarina Steen Carlsson; Jan Astermark; Sharyne Donfield; Erik Berntorp |
Related Documents
:
|
17911509 - Payer costs in patients undergoing uterine artery embolization, hysterectomy, or myomec... 2111109 - Efficient management of diarrhea in the acquired immunodeficiency syndrome (aids). a me... 7633969 - The cost-effectiveness of treatment of short occlusive lesions in the femoropopliteal a... 17962129 - Cost effectiveness analysis of using multiple neuromodalities in treating severe trauma... 11932599 - Carpal tunnel release in the united states and sweden: reimbursement patterns, cost for... 15730579 - Simple decompression or anterior subcutaneous transposition for ulnar neuropathy at the... 6498419 - A comparative evaluation of two psychiatric day hospitals. 9505749 - Pain after vasectomy. 12687829 - Feasibility of pulmonary vein ostia radiofrequency ablation in patients with atrial fib... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Thrombosis and haemostasis Volume: 99 ISSN: 0340-6245 ISO Abbreviation: Thromb. Haemost. Publication Date: 2008 Jun |
Date Detail:
|
Created Date: 2008-06-03 Completed Date: 2008-08-04 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7608063 Medline TA: Thromb Haemost Country: Germany |
Other Details:
|
Languages: eng Pagination: 1060-7 Citation Subset: IM |
Affiliation:
|
Lund University Centre for Health Economics, LUCHE, Lund, Sweden. katarina.steen@luche.lu.se |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Arthralgia / drug therapy, economics, etiology Autoantibodies / blood* Blood Coagulation Factors / economics*, therapeutic use Child Child, Preschool Cost-Benefit Analysis Cross-Over Studies Drug Costs* Factor VIII / immunology* Factor VIIa / economics*, therapeutic use Hemarthrosis / drug therapy, economics*, etiology Hemophilia A / complications, drug therapy, economics*, immunology Hemostatics / economics*, therapeutic use Humans Middle Aged Pain Measurement Patient Satisfaction Recombinant Proteins / economics, therapeutic use Sweden Treatment Outcome Turkey United States |
| Chemical | |
Reg. No./Substance:
|
0/Autoantibodies; 0/Blood Coagulation Factors; 0/Hemostatics; 0/Recombinant Proteins; 0/recombinant FVIIa; 37224-63-8/prothrombin complex concentrates; 9001-27-8/Factor VIII; EC 3.4.21.21/Factor VIIa |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fluid loss does not explain coagulation activation during air travel.
Next Document: Role of membrane cholesterol in platelet calcium signalling in response to VWF and collagen under st...